Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Basilea reports ceftobiprole data

Basilea (SWX:BSLN) on Tuesday said preliminary data showed ceftobiprole met the primary endpoint of non-inferiority vs. ceftazidime

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE